AN2 Therapeutics Q2 net loss widens to $8.2 million from $6.5 million
AN2 Therapeutics reported a second-quarter 2026 net loss of $8.2 million, up from $6.5 million a year earlier, as research and development expenses rose to $6.0 million from $3.2 million. The company had $79.9 million in cash, cash equivalents and investments at June 30, 2026, which it projects will fund operations into 2029 under its current plan.
Key points
- Q2 2026 R&D expenses were $6.0 million, up from $3.2 million in Q2 2025, driven by chemistry manufacturing and controls costs and clinical trial expenses.
- Q2 2026 G&A expenses were $2.9 million, down from $4.0 million a year earlier.
- Net loss per share was $0.18 in Q2 2026, compared with $0.21 in Q2 2025.
- Cash, cash equivalents and investments totaled $79.9 million at June 30, 2026, with runway projected into 2029.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.